CD4 and neoplasm: Most immunotherapy strategies utilize self-antigens in a neutral or TH2 cytokine environment, and the vaccine-induced T cells often have a regulatory CD4+CD25+ Foxp3+ profile that can degrade, rather than enhance, the tumor immune response [72-74].